Page 34 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine FAP-targeted RLT in cancer

https://doi.org/10.1016/s0895-6111(00)00047-1 https://doi.org/10.2967/jnumed.123.265391
65. Gill MR, Falzone N, Du Y, et al., 2017, Targeted radionuclide 70. Feig C, Jones JO, Kraman M, et al., 2013, Targeting CXCL12
therapy in combined-modality regimens. Lancet Oncol, 18: from FAP-expressing carcinoma-associated fibroblasts
e414–e423. synergizes with anti-PD-L1 immunotherapy in pancreatic
https://doi.org/10.1016/S1470-2045(17)30379-0 cancer. Proc Natl Acad Sci U S A, 110: 20212–20217.
66. Chen H, Zhao L, Fu K, et al., 2019, Integrin alpha(v)beta(3)- https://doi.org/10.1073/pnas.1320318110
targeted radionuclide therapy combined with immune 71. Zboralski D, Osterkamp F, Christensen E, et al., 2023,
checkpoint blockade immunotherapy synergistically Fibroblast activation protein targeted radiotherapy induces
enhances anti-tumor efficacy. Theranostics, 9: 7948–7960. an immunogenic tumor microenvironment and enhances
https://doi.org/10.7150/thno.39203 the efficacy of PD-1 immune checkpoint inhibition. Eur J
Nucl Med Mol Imaging, 50: 2621–2635.
67. Choi J, Beaino W, Fecek RJ, et al., 2018, Combined VLA-
4-targeted radionuclide therapy and immunotherapy in a https://doi.org/10.1007/s00259-023-06211-6
mouse model of melanoma. J Nucl Med, 59: 1843–1849. 72. Fu H, Huang J, Sun L, et al., 2022, FAP-targeted radionuclide
https://doi.org/10.2967/jnumed.118.209510 therapy of advanced radioiodine-refractory differentiated
thyroid cancer with multiple cycles of 177 Lu-FAPI-46. Clin
68. Czernin J, Current K, Mona CE, et al., 2021, Immune- Nucl Med, 47: 906–907.
checkpoint blockade enhances Ac-PSMA617 efficacy in a
225
mouse model of prostate cancer. J Nucl Med, 62: 228–231. https://doi.org/10.1097/RLU.0000000000004260
https://doi.org/10.2967/jnumed.120.246041 73. Rao Z, Zhang Y, Liu L, et al., 2023, 177 LuLu-FAP-2286
therapy in a case of right lung squamous cell carcinoma
69. Esfahani SA, De Aguiar Ferreira C, Summer P, et al., 2023,
Addition of peptide receptor radiotherapy to immune with systemic metastases. Eur J Nucl Med Mol Imaging, 50:
checkpoint inhibition therapy improves outcomes in 1266–1267.
neuroendocrine tumors. J Nucl Med, 64: 1056–1061. https://doi.org/10.1007/s00259-022-06048-5

Volume 1 Issue 2 (2023) 13 https://doi.org/10.36922/arnm.1667